Insights on where healthcare gaps create opportunity
Exploring the ideas, innovations, and healthcare system changes shaping better decisions, better care, and better adoption.
Explore news and insights below
Unmet demand for testosterone in menopause care creates an investable gap — if safety and regulatory questions are solved
Surging patient demand and sparse female-specific products have exposed a commercial and scientific opportunity in postmenopausal testosterone therapy. Investors who target formulation, diagnostics, and rigorous evidence generation can shape a nascent sub-sector, but must price in long-term safety and regulatory risk.
EMA’s women’s health roadmap is a regulatory inflection point — what investors should build for now
The European Medicines Agency is formalising a roadmap to close sex-specific data gaps in drug development by late 2026. That shift creates both near-term compliance costs for sponsors and a durable demand signal for products and services that deliver sex-disaggregated evidence across the drug lifecycle.
Small randomized trial in UK opens pathway to stopping lifelong heart drugs for some HER2 breast cancer survivors—what investors in women's health should watch next
A UCL-led randomized study suggests many women who recover from HER2 therapy–related cardiac injury can discontinue heart failure medications without short-term loss of function. The result reframes risks, creates demand for surveillance tools, and narrows an investable niche inside cardio-oncology.
NHS scales mailed HPV self-sampling to reach four million overdue screens, shifting cervical screening into decentralized care
England's decision to mail at-home HPV swabs to women who have missed invitations turns a persistent public-health gap into a large, procurement-driven market. For investors, the move accelerates demand for self-collection kits, laboratory capacity, logistics and digital follow-up services that close the screening-to-treatment loop.
Essity’s $284M Brazil buy is a play for scale in femcare — strategic implications for investors and innovators
Essity’s agreement to acquire three high-volume period-care labels and local manufacturing in Brazil is more than routine consolidation; it signals a targeted push to control supply, distribution, and innovation levers in one of the world’s largest femcare markets. For investors, the deal highlights where capital will flow next in women's hygiene: scale-enabled product evolution, supply-chain modernization, and partnership opportunities for nimble femtech entrants.
AU and WHO reset the playbook for African health systems, creating clearer pathways for women's health investment
The renewed AU–WHO memorandum of understanding turns continent-level policy alignment into a practical set of priorities that lower structural barriers for investors in maternal and reproductive health, local pharma, digital platforms, and workforce solutions. Investors should reweight exposure to companies and consortia positioned to deliver on RMNCAH, local manufacturing, regulatory harmonization, and emergency-resilient services.
Public funding is pivoting menopause femtech from consumer demos to clinical and workplace validation
A new cross-border EU-backed program is using regional healthcare partners to test market-ready menopause solutions, creating early procurement and evidence pathways that reduce adoption risk. For investors this signals a shift toward femtech products that must prove clinical and implementation value, not just consumer traction.
Unmet demand for testosterone in menopause care creates an investable gap — if safety and regulatory questions are solved
Surging patient demand and sparse female-specific products have exposed a commercial and scientific opportunity in postmenopausal testosterone therapy. Investors who target formulation, diagnostics, and rigorous evidence generation can shape a nascent sub-sector, but must price in long-term safety and regulatory risk.
Read more →EMA’s women’s health roadmap is a regulatory inflection point — what investors should build for now
The European Medicines Agency is formalising a roadmap to close sex-specific data gaps in drug development by late 2026. That shift creates both near-term compliance costs for sponsors and a durable demand signal for products and services that deliver sex-disaggregated evidence across the drug lifecycle.
Read more →Small randomized trial in UK opens pathway to stopping lifelong heart drugs for some HER2 breast cancer survivors—what investors in women's health should watch next
A UCL-led randomized study suggests many women who recover from HER2 therapy–related cardiac injury can discontinue heart failure medications without short-term loss of function. The result reframes risks, creates demand for surveillance tools, and narrows an investable niche inside cardio-oncology.
Read more →NHS scales mailed HPV self-sampling to reach four million overdue screens, shifting cervical screening into decentralized care
England's decision to mail at-home HPV swabs to women who have missed invitations turns a persistent public-health gap into a large, procurement-driven market. For investors, the move accelerates demand for self-collection kits, laboratory capacity, logistics and digital follow-up services that close the screening-to-treatment loop.
Read more →Essity’s $284M Brazil buy is a play for scale in femcare — strategic implications for investors and innovators
Essity’s agreement to acquire three high-volume period-care labels and local manufacturing in Brazil is more than routine consolidation; it signals a targeted push to control supply, distribution, and innovation levers in one of the world’s largest femcare markets. For investors, the deal highlights where capital will flow next in women's hygiene: scale-enabled product evolution, supply-chain modernization, and partnership opportunities for nimble femtech entrants.
Read more →AU and WHO reset the playbook for African health systems, creating clearer pathways for women's health investment
The renewed AU–WHO memorandum of understanding turns continent-level policy alignment into a practical set of priorities that lower structural barriers for investors in maternal and reproductive health, local pharma, digital platforms, and workforce solutions. Investors should reweight exposure to companies and consortia positioned to deliver on RMNCAH, local manufacturing, regulatory harmonization, and emergency-resilient services.
Read more →Public funding is pivoting menopause femtech from consumer demos to clinical and workplace validation
A new cross-border EU-backed program is using regional healthcare partners to test market-ready menopause solutions, creating early procurement and evidence pathways that reduce adoption risk. For investors this signals a shift toward femtech products that must prove clinical and implementation value, not just consumer traction.
Read more →Stay Informed
Women's health is moving fast. Keep up.
Get Fern's latest research, investment commentary, and event invitations delivered to your inbox.